TY - JOUR
T1 - Delivery of intravenous anti-cancer therapy at home versus in hospital or community settings for adults with cancer (Protocol)
AU - Grobler, Liesl
AU - O'Connor, Denise
AU - Rischin, Danny
AU - Putrik, Polina
AU - Karnon, Jonathan
AU - Rischin, Kobi J.
AU - McKenzie, Bayden J.
AU - Buchbinder, Rachelle
N1 - Funding Information:
We acknowledge the help and support of Cochrane Effective Practice and Organisation of Care (EPOC). The authors would also like to thank the following editors and peer referees who provided comments to improve the protocol: Luciana Ballini (Contact Editor, Cochrane EPOC) Nicole Skoetz (Network Senior Editor, Cochrane Cancer Network) Paul Miller (Information Specialist, Cochrane EPOC) JC Han (Assistant Managing Editor, Cochrane EPOC) Lani Jane Chong (Consumer, external) Pippa Corrie (Content expert, external) We also thank Andrea Takeda for copy-editing the protocol. National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Effective Practice and Organisation of Care (EPOC) Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic Reviews Programme, NIHR, National Health Service (NHS), or the Department of Health. The Australasian Satellite of the Cochrane EPOC Group is supported by Monash University and Cabrini Health.
Publisher Copyright:
Copyright © 2022 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
PY - 2022/5/3
Y1 - 2022/5/3
N2 - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the safety, patient preference for, and cost of intravenous anti-cancer therapy (chemotherapy or immunotherapy) delivered at home as an alternative to the same intravenous anti-cancer therapy regimen delivered in a hospital or community settings, in adults with cancer.
AB - Objectives: This is a protocol for a Cochrane Review (intervention). The objectives are as follows:. To assess the safety, patient preference for, and cost of intravenous anti-cancer therapy (chemotherapy or immunotherapy) delivered at home as an alternative to the same intravenous anti-cancer therapy regimen delivered in a hospital or community settings, in adults with cancer.
UR - http://www.scopus.com/inward/record.url?scp=85129356960&partnerID=8YFLogxK
U2 - 10.1002/14651858.CD014861
DO - 10.1002/14651858.CD014861
M3 - Article
AN - SCOPUS:85129356960
SN - 1465-1858
VL - 2022
JO - Cochrane Database of Systematic Reviews
JF - Cochrane Database of Systematic Reviews
IS - 5
M1 - CD014861
ER -
